The pathogenic importance of IL-4 and IL-13 has recently been reinforced by the excellent treatment response of patients with AD to the anti-IL-4 receptor α (IL-4Rα, IL4R) antibody dupilumab, which inhibits both IL-4 and IL-13 signals [44,118]. Here, IL13 is linked to Alzheimer disease.